Perbandingan Kualitas Hidup Penderita Kanker Ovarium Epitelial yang Diberikan Kemoterapi Regimen Paclitaxel dan Carboplatin dengan Regimen Cyclophospamide, Adriamicyn dan Cisplatin di RSUP Dr. Sardjito

https://doi.org/10.22146/jkr.35428

Ibnu Ahyar(1*), Irwan Taufiqurrachman(2), Ardhanu Kusumanto(3)

(1) Departement of Obstetrics and Gynecology, Faculty of Medicine, University of Gadjah Mada
(2) Departement of Obstetrics and Gynecology, Faculty of Medicine, University of Gadjah Mada
(3) Departement of Obstetrics and Gynecology, Faculty of Medicine, University of Gadjah Mada
(*) Corresponding Author

Abstract


Background: Epithelial ovarian cancer is the dominant type of ovarian cancer. Platinum and Taxane regiment has been proved to increase the survival rate of ovarian cancer patients

Objective: To compare the quality of life of ovarian cancer patients who got Paclitaxel and Carboplatin regiments with Cyclophosphamide, Adriamycin and Cisplatin regiments and risk factors which influence them

Method: The design of the study was retrospective cohort. The total subjects were 156 ovarian cancer patients who consisted of 79 patients with paclitaxel and carboplatin regiments and dan 77 patients who got cyclophospamide, adriamicyn dan cisplatin regiments in DR. Sardjito hospital, Yogyakarta. The quality of life was measured with EORTC QLQ-C30. The data distribution were tested with KolmogorovSmirnov and analysed with D Chi-Squaretest for categorical data and Mann-Whitney for continuous data. Multivariable Analysis was done with logistic regression.

Result and Discussion: The bivariable analysis of ovarian cancer stage and the quality of life showed that early stage of ovarian cancer patients had quality of life 19,068 times higher than advance stage of ovarian cancer patients (RR 19,068; 95% CI 2,590-140,362). There were signicant differences in quality of life in ovarian cancer patients with low body mass index <18,5 compared to normal body mass index as well as the titer of tumor marker Ca125. Multivariable analysis showed that there was no significant difference in quality of life between ovarian cancer patients who got Paclitaxel plus Carboplatin and ovarian cancer patients who got Cyclophospamide, Adriamicyn plus Cisplatin.

Conclusion: there was no significant difference in quality of life between ovarian cancer patients who got Paclitaxel plus Carboplatin and ovarian cancer patients who got Cyclophospamide, Adriamicyn plus Cisplatin in DR. Sardjito Hospital, Yogyakarta.

Keywords: Quality of life, ovarian cancer, paclitaxel plus carboplatin regiment, cyclophospamide, adriamicyn plus cisplatin regiment.


Keywords


Quality of life; ovarian cancer; paclitaxel plus carboplatin regiment; cyclophospamide; adriamicyn plus cisplatin regiment.

Full Text:

PDF PDF PDF


References

  1. Hilpert, F. et al.,. 2017. Epithelial ovarian cancer. Ther Umsch, 64(7), pp.375-380. 
  2. Partridge, E.E. & Barnes, M.N.,. 1999. Epithelial Ovarian Cancer : Prevention , Diagnosis , and Treatment. Ca—A cancer Journal for Clinicians.
  3. Glaze, S. et al.,. 2013. Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative. Journal of obstetrics and gynaecology Canada : JOGC = Journal d’obstetrique et gynecologie du Canada : JOGC, 35(1), pp.61–67.
  4. Hidaka, T. et al., 2006. Paclitaxel/carboplatin versus cyclophosphamide/ adriamycin/ cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. Journal of Obstetrics and Gynaecology Research, 32(3), pp.330–337
  5. Michael, M. & Tannock, I.F., 1998. Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment, CMAJ: Canadian Medical Association Journal, 158(13), pp.1727–1734.
  6. Bert, S., 1996. Quality of life and pharmacoeconomics in clinical trials.
  7. Jensen, S. & Cella, D., 2014. Quality of Life in Patients with Ovarian Cancer. Advances in Diagnosis and Management of Ovarian Cancer, pp.241–260.
  8. Greimel, E.R. et al., 2006. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module.
  9. Berners-Price, S.J. & Appleton, T.G., 2000. The Chemistry of Cisplatin in Aqueous Solution BT - Platinum-Based Drugs in Cancer Therapy. In L. R. Kelland & N. P. Farrell, eds. Totowa, NJ: Humana Press, pp. 3–35.
  10. Luvero, D., Milani, A. & Ledermann, J.A., 2014. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), pp.229–39.
  11. Das, U. et al., 2014. Assessment of nutritional status of gynecological cancer cases in India and comparison of subjective and objective nutrition.
  12. Mardas, M. et al., 2015. Dietary habits changes and quality of life in patients undergoing chemotherapy for epithelial ovarian cancer. Supportive care 
  13. in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 23(4), pp.1015–23.
  14. Teng, F.F. et al., 2014. Determinants of quality of life in ovarian cancer survivors: A pilot study. Journal of Obstetrics & Gynaecology Canada, 36(8), pp.708



DOI: https://doi.org/10.22146/jkr.35428

Article Metrics

Abstract views : 1332 | views : 1406 | views : 2037 | views : 2137

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Jurnal Kesehatan Reproduksi



Jurnal Kesehatan Reproduksi Indexed by:

 



SEKRETARIAT JURNAL KESEHATAN REPRODUKSI
Departemen Obstetri dan Ginekologi, FK-KMK, UGM/RS Dr. Sardjito
Jl. Kesehatan No. 1, Sekip Utara, Yogyakarta 55281
Tlp: (0274) 511329 / Faks: (0274) 544003
Email: jurnal.kesehatanreproduksi@ugm.ac.id
Cp: Dwi Astuti +6281802698043